Related references
Note: Only part of the references are listed.Structure-Activity Relationship Studies on Clinically Relevant HIV-1 NNRTIs
R. K. Rawal et al.
CURRENT MEDICINAL CHEMISTRY (2012)
Rational Design of Potent Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase
Pek Chong et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Lead optimization at C-2 and N-3 positions of thiazolidin-4-ones as HIV-1 non-nucleoside reverse transcriptase inhibitors
Vanangamudi Murugesan et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2011)
Single HA2 Mutation Increases the Infectivity and Immunogenicity of a Live Attenuated H5N1 Intranasal Influenza Vaccine Candidate Lacking NS1
Brigitte M. Krenn et al.
PLOS ONE (2011)
Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: A review of the last 20 years (1989-2009)
Marie-Pierre de Bethune
ANTIVIRAL RESEARCH (2010)
Crystal Structures of HIV-1 Reverse Transcriptase with Etravirine (TMC125) and Rilpivirine (TMC278): Implications for Drug Design
Eric B. Lansdon et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
AutoDock4 and AutoDockTools4: Automated Docking with Selective Receptor Flexibility
Garrett M. Morris et al.
JOURNAL OF COMPUTATIONAL CHEMISTRY (2009)
Synthesis and Biological Evaluation of C-5 Methyl Substituted 4-Arylthio and 4-Aryloxy-3-Iodopyridin-2(1H)-one Type Anti-HIV Agents
Jerome Guillemont et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
CoMFA and CoMSIA studies on thiazolidin-4-one as anti-HIV-1 agents
Vanangamudi Murugesan et al.
JOURNAL OF MOLECULAR GRAPHICS & MODELLING (2009)
Design and synthesis of 2-(2,6-dibromophenyl)-3-heteroaryl-1, 3-thiazolidin-4-ones as anti-HIV agents
Ravindra K. Rawal et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2008)
Combining docking, molecular dynamics and the linear interaction energy method to predict binding modes and affinities for non-nucleoside inhibitors to HIV-1 reverse transcriptase
Jens Carlsson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: Strategic flexibility explains potency against resistance mutations
Kalyan Das et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse transcriptase
Jingshan Ren et al.
VIRUS RESEARCH (2008)
Molecular surface features in modeling the HIV-1 RT inhibitory activity of 2-(2,6-disubstituted phenyl)-3-(substituted pyrimidin-2-yl)-thiazolidin-4-ones
Ravindra K. Rawal et al.
QSAR & COMBINATORIAL SCIENCE (2007)
Structure-activity relationship in the 3-iodo-4-phenoxypyridinone (IOPY) series: The nature of the C-3 substituent on anti-HIV activity
Abdellah Benjahad et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2007)
PANTHER version 6: protein sequence and function evolution data with expanded representation of biological pathways
Huaiyu Mi et al.
NUCLEIC ACIDS RESEARCH (2007)
Potent nonnucleoside reverse transcriptase inhibitors target HIV-1 Gag-Pol
Anna Figueiredo et al.
PLOS PATHOGENS (2006)
Computer-aided molecular design of highly potent HIV-1 RT inhibitors: 3D QSAR and molecular docking studies of efavirenz derivatives
P. Pungpo et al.
SAR AND QSAR IN ENVIRONMENTAL RESEARCH (2006)
CUPSAT: prediction of protein stability upon point mutations
Vijaya Parthiban et al.
NUCLEIC ACIDS RESEARCH (2006)
Isoelectric point determination of proteins and other macromolecules: Oscillating method
A Sillero et al.
COMPUTERS IN BIOLOGY AND MEDICINE (2006)
2-(Aryl)-3-furan-2-ylmethyl-thiazolidin-4-ones as selective HIV-RT inhibitors
RK Rawal et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2005)
Crystal structures for HIV-1 reverse transcriptase in complexes with three pyridinone derivatives: A new class of non-nucleoside inhibitors effective against a broad range of drug-resistant strains
DM Himmel et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
4-benzyl and 4-benzoyl-3-dimethylaminopyridin-2 (1H)-ones:: In vitro evaluation of new c-3-amino-substituted and c-5,6-alkyl-substituted analogues against clinically important HIV mutant strains
A Benjahad et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
CP-MLR/PLS directed structure-activity modeling of the HIV-1 RT inhibitory activity of 2,3-diaryl-1,3-thiazolidin-4-ones
YS Prabhakar et al.
QSAR & COMBINATORIAL SCIENCE (2004)
VADAR: a web server for quantitative evaluation of protein structure quality
L Willard et al.
NUCLEIC ACIDS RESEARCH (2003)
SIFT: predicting amino acid changes that affect protein function
PC Ng et al.
NUCLEIC ACIDS RESEARCH (2003)
Twenty years of HIV-1 research: what the future holds
N Imami et al.
NATURE IMMUNOLOGY (2003)
Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors
J Ren et al.
JOURNAL OF MOLECULAR BIOLOGY (2001)
Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase
J Ren et al.
STRUCTURE (2000)
A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1
CJ Petropoulos et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2000)
Share Paper
